Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

2.

Human papillomavirus vaccination: the population impact.

Lee LY, Garland SM.

F1000Res. 2017 Jun 12;6:866. doi: 10.12688/f1000research.10691.1. eCollection 2017. Review.

3.

Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.

Perkins RB, Lin M, Wallington SF, Hanchate A.

Sex Transm Dis. 2017 Jun;44(6):365-370. doi: 10.1097/OLQ.0000000000000615.

PMID:
28499288
4.

Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study.

Cocchio S, Baldovin T, Bertoncello C, Buja A, Furlan P, Saia M, Baldo V.

BMC Infect Dis. 2017 Apr 5;17(1):249. doi: 10.1186/s12879-017-2361-5.

5.

HPV-6 Molecular Variants Association With the Development of Genital Warts in Men: The HIM Study.

Flores-Díaz E, Sereday KA, Ferreira S, Sirak B, Sobrinho JS, Baggio ML, Galan L, Silva RC, Lazcano-Ponce E, Giuliano AR, Villa LL, Sichero L; HIM Study group.

J Infect Dis. 2017 Feb 15;215(4):559-565. doi: 10.1093/infdis/jiw600.

PMID:
28011919
6.

Systematic Review and Meta-Analysis of Interventions to Improve Access and Coverage of Adolescent Immunizations.

Das JK, Salam RA, Arshad A, Lassi ZS, Bhutta ZA.

J Adolesc Health. 2016 Oct;59(4S):S40-S48. doi: 10.1016/j.jadohealth.2016.07.005. Review.

7.

Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement.

Saslow D, Andrews KS, Manassaram-Baptiste D, Loomer L, Lam KE, Fisher-Borne M, Smith RA, Fontham ET; American Cancer Society Guideline Development Group.

CA Cancer J Clin. 2016 Sep;66(5):375-85. doi: 10.3322/caac.21355. Epub 2016 Jul 19. Review.

8.

Update on the new 9-valent vaccine for human papillomavirus prevention.

Yang DY, Bracken K.

Can Fam Physician. 2016 May;62(5):399-402. Epub 2016 May 12. Review.

9.

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.

Boiron L, Joura E, Largeron N, Prager B, Uhart M.

BMC Infect Dis. 2016 Apr 16;16:153. doi: 10.1186/s12879-016-1483-5.

10.

Incidence, Duration, Persistence, and Factors Associated With High-risk Anal Human Papillomavirus Persistence Among HIV-negative Men Who Have Sex With Men: A Multinational Study.

Nyitray AG, Carvalho da Silva RJ, Chang M, Baggio ML, Ingles DJ, Abrahamsen M, Papenfuss M, Lin HY, Salmerón J, Quiterio M, Lazcano-Ponce E, Villa LL, Giuliano AR.

Clin Infect Dis. 2016 Jun 1;62(11):1367-1374. doi: 10.1093/cid/ciw140. Epub 2016 Mar 8.

11.

Interventions to increase HPV vaccination coverage: A systematic review.

Smulian EA, Mitchell KR, Stokley S.

Hum Vaccin Immunother. 2016 Jun 2;12(6):1566-88. doi: 10.1080/21645515.2015.1125055. Epub 2016 Feb 2.

12.

HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee.

Sauvageau C, Dufour-Turbis C.

Hum Vaccin Immunother. 2016 Jun 2;12(6):1560-5. doi: 10.1080/21645515.2015.1112474. Epub 2015 Nov 10.

13.

Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.

Dominiak-Felden G, Gobbo C, Simondon F.

PLoS One. 2015 Jul 6;10(7):e0132404. doi: 10.1371/journal.pone.0132404. eCollection 2015. Erratum in: PLoS One. 2016;11(1):e0148665.

14.

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Mugo N, Ansah NA, Marino D, Saah A, Garner EI.

Hum Vaccin Immunother. 2015;11(6):1323-30. doi: 10.1080/21645515.2015.1008877.

15.

Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.

Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R.

Adv Ther. 2015 Jan;32(1):10-30. doi: 10.1007/s12325-015-0178-4. Epub 2015 Jan 27. Review.

16.

Immunoprevention of human papillomavirus-associated malignancies.

Wang JW, Hung CF, Huh WK, Trimble CL, Roden RB.

Cancer Prev Res (Phila). 2015 Feb;8(2):95-104. doi: 10.1158/1940-6207.CAPR-14-0311. Epub 2014 Dec 8. Review.

17.

Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.

Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.

PLoS One. 2014 Feb 5;9(2):e88323. doi: 10.1371/journal.pone.0088323. eCollection 2014.

18.

Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs.

Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J.

South Asian J Cancer. 2013 Oct;2(4):187-92. doi: 10.4103/2278-330X.119877.

19.

Development and initial feedback about a human papillomavirus (HPV) vaccine comic book for adolescents.

Katz ML, Oldach BR, Goodwin J, Reiter PL, Ruffin MT 4th, Paskett ED.

J Cancer Educ. 2014 Jun;29(2):318-24. doi: 10.1007/s13187-013-0604-8.

20.

The burden of human papillomavirus infections and related diseases in sub-saharan Africa.

De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP.

Vaccine. 2013 Dec 29;31 Suppl 5:F32-46. doi: 10.1016/j.vaccine.2012.07.092. Review.

Supplemental Content

Support Center